Stock Monitor: Eagle Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 06, 2018 / Active-Investors.com has just released a free research report on Mylan N.V. (NASDAQ: MYL). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MYL as the Company's latest news hit the wire. On March 02, 2018, the Company announced that it is planning to launch two new low-cost HIV treatments, Symfi Lo?, and Cimduo? in the United States, which were approved by the US Food and Drug Administration (FDA) in February 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), which also belongs to the Healthcare sector as the Company Mylan. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=EGRX

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Mylan most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=MYL

These Launches will Extend Mylan's Global Antiretroviral Platform

Symfi Lo will be launched in the coming weeks and Cimduo will be introduced in Q2 2018. These launches will extend the Company's global antiretroviral (ARV) platform and help address the high cost of HIV treatment in the US. Mylan is the world's largest producer of HIV/AIDS drugs and the Company's total spending for HIV medications in the US exceeds $20 billion annually.

For reducing the high cost of HIV treatment in the US, Symfi Lo's list price will be discounted significantly from the wholesale acquisition cost (WAC) of any other STR on the US market today. Cimduo's list price will likewise be at a significant discount to any other tenofovir-based double combination product on the US market.

Upcoming Launches of Symfi Lo and Cimduo Will Help Deliver Significant Savings to the Healthcare System

Heather Bresch, Chief Executive Officer of Mylan, mentioned that as the world's largest supplier of antiretrovirals by volume, the Company is deeply committed to expanding access to treatment for people living with HIV. For a decade, Mylan has helped transform the level of access to high-quality, affordable HIV medications in developing countries. Heather added that the Company is happy to bring that same passion to the US with the upcoming launches of Symfi Lo and Cimduo and help deliver significant savings to the healthcare system.

Symfi Lo is the First Combination Regimen in the US with a Reduced Dose of Efavirenz

Symfi Lo is an STR formulated with a 400 mg dose of efavirenz, which is one-third less than the dose originally approved in 1998. The fixed-dose combination was recommended by the World Health Organization in 2016 as an alternative first-line therapy for adults living with HIV infection. Since March 2017, Mylan has sold the product overseas upon the receipt of Tentative Approval by FDA under the US President's Emergency Plan for AIDS Relief (PEPFAR) program. Worldwide, Mylan supplied the regimen to more than one million patients in 2017.

Mylan Expanded Access to HIV Medicines with Launch of First Generic Sustiva® Tablets

In February 2018, Mylan announced the US launch of Efavirenz Tablets USP - 600 mg, the first generic version of Bristol-Myers Squibb's Sustiva®. The product is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type-1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. According to the FDA's approval letter, Mylan was one of the first applicants to submit a substantially complete ANDA for Efavirenz Tablets USP - 600 mg, containing a Paragraph IV certification, and is eligible for 180 days of generic drug exclusivity.

About Symfi Lo and Cimduo

Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) 400 mg/300 mg/300 mg tablets is a once-daily, single-tablet regimen (STR) and is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 35 kg.

Cimduo? (lamivudine and tenofovir disoproxil fumarate) 300 mg/300 mg tablets is a once-daily combination of two nucleo(t)side reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.

About Mylan N.V.

Founded in 1961 and headquartered in Canonsburg, Pennsylvania, Mylan is a global healthcare company focused on making high quality medicines. The Company has one of the broadest and most diverse portfolios, with more than 7,500 marketed products that include prescription generic and brand-name medicines, and consumer healthcare products.

Stock Performance Snapshot

March 05, 2018 - At Monday's closing bell, Mylan's stock climbed 1.39%, ending the trading session at $41.54.

Volume traded for the day: 3.80 million shares.

Stock performance in the last three-month ? up 13.71%; and previous six-month period ? up 31.96%

After yesterday's close, Mylan's market cap was at $22.13 billion.

Price to Earnings (P/E) ratio was at 27.03.

The stock is part of the Healthcare sector, categorized under the Drugs - Generic industry. This sector was up 1.0% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors